ICUS Weekly News Monitor 8-11-17

Business Journal News Network

Crouse Health unveils new ultrasound-imaging test to detect liver, kidney cancer

Aug 4, 2017

Author:  Eric Reinhardt

SYRACUSE, N.Y. — Crouse Health has introduced a new imaging test to detect liver and kidney cancers that it says “up until now has only been available in larger markets such as Boston, New York City, and Philadelphia.”

It’s called contrast-enhanced ultrasound (CEUS).

The procedure uses contrast agents called “microbubbles,” Dr. Thomas Green, chief of radiology at Crouse Health, said in a news release.

Green recently took special training in CEUS at Thomas Jefferson University in Philadelphia, Crouse Health said.

The microbubbles are “dramatically improving” the precision of diagnostic sonograms and expanding the clinical scope of a widely used, imaging modality.

Once injected in the patient’s arm, the microbubbles go directly to the suspected area of the liver or kidney, improving visualization of blood flow, the cardiovascular system and the movement of blood into vital organs, particularly the liver and kidney.

“Liver and renal lesions are very common,” Green said. “Differentiating benign from malignant can be difficult and expensive. Traditionally, this has been done with enhanced CT scanning, enhanced MRI or sometimes nuclear medicine.”

CEUS has advantages over all three methods, according to Green.

For example, CEUS doesn’t involve radiation, as CT and nuclear medicine do. It also doesn’t generate concerns about renal function or iodine contrast allergy.

It also doesn’t result in “issues” with metallic implants, internal pacemakers or claustrophobia, as an MRI (magnetic resonance imaging) procedure would produce.

And, according to Green, the test is “significantly less expensive” than other options, which is “important, especially with today’s high-deductible insurance plans.”

Crouse is expecting the number of cases using the new ultrasound-imaging test will increase once providers learn of its availability, Green adds.

 
 
 
 
 
 

Dove Medical Press

Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer

Jul 26, 2017

Authors:   Meng Wu,1,2 Ying Wang,3 Yiru Wang,2 Mingbo Zhang,2 Yukun Luo,2 Jie Tang,2 Zhigang Wang,4 Dong Wang,5 Lan Hao,4 Zhibiao Wang6

1School of Medicine, Nankai University, Tianjin, 2Department of Ultrasound, Chinese PLA General Hospital, Beijing, 3Wuhan Textile University, Wuhan, 4Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, 5Department of Ultrasound, The First Affiliated Hospital of Chongqing Medical University, 6College of Biomedical Engineering, Chongqing Medical University, Chongqing, People’s Republic of China

Published 26 July 2017 Volume 2017:12 Pages 5313—5330

  1.  https://doi.org/10.2147/IJN.S136032

Abstract:

In the current study, we synthesized prostate cancer-targeting poly(lactide-co-glycolic acid) (PLGA) nanobubbles (NBs) modified using A10-3.2 aptamers targeted to prostate-specific membrane antigen (PSMA) and encapsulated paclitaxel (PTX). We also investigated their impact on ultrasound (US) imaging and therapy of prostate cancer. PTX-A10-3.2-PLGA NBs were developed using water-in-oil-in-water (water/oil/water) double emulsion and carbodiimide chemistry approaches. Fluorescence imaging together with flow cytometry verified that the PTX-A10-3.2-PLGA NBs were successfully fabricated and could specifically bond to PSMA-positive LNCaP cells. We speculated that, in vivo, the PTX-A10-3.2-PLGA NBs would travel for a long time, efficiently aim at prostate cancer cells, and sustainably release the loaded PTX due to the improved permeability together with the retention impact and US-triggered drug delivery. The results demonstrated that the combination of PTX-A10-3.2-PLGA NBs with low-frequency US achieved high drug release, a low 50% inhibition concentration, and significant cell apoptosis in vitro. For mouse prostate tumor xenografts, the use of PTX-A10-3.2-PLGA NBs along with low-frequency US achieved the highest tumor inhibition rate, prolonging the survival of tumor-bearing nude mice without obvious systemic toxicity. Moreover, LNCaP xenografts in mice were utilized to observe modifications in the parameters of PTX-A10-3.2-PLGA and PTX-PLGA NBs in the contrast mode and the allocation of fluorescence-labeled PTX-A10-3.2-PLGA and PTX-PLGA NBs in live small animals and laser confocal scanning microscopy fluorescence imaging. These results demonstrated that PTX-A10-3.2-PLGA NBs showed high gray-scale intensity and aggregation ability and showed a notable signal intensity in contrast mode as well as aggregation ability in fluorescence imaging. In conclusion, we successfully developed an A10-3.2 aptamer and loaded PTX-PLGA multifunctional theranostic agent for the purpose of obtaining US images of prostate cancer and providing low-frequency US-triggered therapy of prostate cancer that was likely to constitute a strategy for both prostate cancer imaging and chemotherapy.

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:

dentons-logo2

silver-level

Toshiba Medical logo resized

samsung-logo

siemens-new-original

philips-icus-logo

mindray

Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS Weekly News Monitors ICUS Weekly News Monitor 8-11-17